Evidence map›Paper›PMID 32212859›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2020

Regression from prediabetes to normal glucose regulation: State of the science.

Anthony Sallar, Samuel Dagogo-Jack

Abstract readReview
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Observational
  9. Modern Management of CKM Syndrome: Use of GLP-1 Receptor Agonists in a Multidisciplinary Setting-Expert Group Recommendations from Kuwait.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  10. Review
  11. Review
  12. Prediabetes in Transition: Insights from the Tehran Lipid and Glucose Study.International journal of endocrinology and metabolism · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anthony SallarDivision of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, Memphis, TN 38163, USA.ORCID 0000-0002-2111-6067
Samuel Dagogo-JackDivision of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, Memphis, TN 38163, USA.ORCID 0000-0001-5318-9677

Funding

Pathobiology of Prediabetes in A Bi-Racial CohortR01DK067269 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DAGOGO-JACK, M.D., D.SC., SAMUEL · 2006 to 2017
$6.1M
NIDDK NIH HHS R01 DK067269
6 · The paper itself

Abstract

impact statementPrediabetes increases the risks of future type 2 diabetes (T2D) and vascular complications, risks that can be prevented by restoring normal glucose regulation (NGR). Few studies have pre-specified reversal of prediabetes and restoration of NGR as primary outcome, and current approaches that prevent T2D in people with prediabetes do not always reverse the prediabetes. The present review focuses on studies that have assessed reversal of the prediabetes, and discusses known and emerging predictors of prediabetes. We argue that fuller knowledge of such predictors could inform the discovery of novel, targeted interventions for reversing prediabetes.

Indexed as

AnimalsBlood GlucoseDiabetes Mellitus, Type 2Disease ProgressionGlucose IntoleranceHumansPrediabetic StateBlood Glucoseimpaired fasting glucoseimpaired glucose tolerancelifestylenormal glucose regulationPrediabetes reversal

Identifiers

PMID32212859
PMCPMC7268926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.